Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

T-helper type 2 cell-directed therapy for asthma.

L Cohn1, A Ray

  • 1Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, 333 Cedar Street, PO Box 208057, 06520-8057, New Haven, CT, USA. lauren.cohn@yale.edu

Pharmacology & Therapeutics
|January 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Parkinsonism with akinetic mutism following osmotic demyelination syndrome in a SARS-CoV-2 infected elderly diabetic woman: A case report.

Neurologia·2022
Same author

Search for Subsolar-Mass Binaries in the First Half of Advanced LIGO's and Advanced Virgo's Third Observing Run.

Physical review letters·2022
Same author

The musculoskeletal manifestations of haemophilia: a review of the imaging findings.

Clinical radiology·2022
Same author

Apparent missing tooth due to traumatic dental intrusion during airway management.

Anaesthesia reports·2022
Same author

Protective effects of L-arginine on cognitive deficits and biochemical parameters in an experimental model of type-2 diabetes mellitus induced Alzheimer's disease in rats.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2022
Same author

Prevalence and prospective evaluation of cognitive dysfunctions after SARS due to SARS-CoV-2 virus. The COgnitiVID study.

Revue neurologique·2022
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
Same journal

A-type potassium channels in pain signaling: Fundamental mechanisms and pathophysiological roles.

Pharmacology & therapeutics·2026
Same journal

GPCR crosstalk beyond obligate dimerisation: Effector coincidence detection, compartmentation, and pharmacological implications.

Pharmacology & therapeutics·2026
See all related articles

T-helper type 2 (Th2) cells and their cytokines drive asthma pathogenesis. This review explores Th2 cell mechanisms and discusses current and novel immunotherapies targeting Th2 responses for asthma treatment.

Area of Science:

  • Immunology
  • Respiratory Medicine
  • Allergy

Background:

  • Asthma is a chronic airway inflammation.
  • T-helper type 2 (Th2) cells and cytokines are implicated in asthma pathology.
  • Understanding Th2 cell roles is crucial for effective asthma management.

Purpose of the Study:

  • To review evidence linking Th2 cells to asthma.
  • To discuss mechanisms controlling Th2 cell differentiation in the airways.
  • To explore therapeutic strategies targeting Th2 responses.

Main Methods:

  • Literature review of human and animal studies.
  • Analysis of cellular and molecular mechanisms of Th2 differentiation.
  • Discussion of traditional and novel immunomodulatory therapies.

Related Experiment Videos

Main Results:

  • Th2 cells and their cytokines are key drivers of asthma.
  • Th2 cell differentiation is regulated by specific cellular and molecular pathways.
  • Existing therapies can modulate Th2 function, while new strategies aim to block differentiation or neutralize cytokines.

Conclusions:

  • Th2 cells are central to asthma pathophysiology.
  • Targeting Th2 cell differentiation and function offers promising therapeutic avenues.
  • Future treatments may involve blocking Th2 responses or redirecting immunity toward Th1 pathways.